A Crystallographic-Based Fragment Screen Against Human BRD4 Bromodomain 1
Poster Oct 17, 2012
Hubbard P, Ritchie A, Hughes S, Lipkin M, Blackaby W & MacLeod A
Given that DMSO is a well known competitor of compound binding in human BRD4 bromodomain 1, we initially solved the crystal structure of this protein soaked in the presence of DMSO. Confirming that DMSO binds to the acetyllysine binding site, we commenced the fragment screen using ethanol as the compound solvent, allowing solvent to evaporate before solutions for protein crystal soaks were prepared. Fragments were batched into groups of three based on shape diversity and chemical compatibility, and datasets from soaked crystals that spanned the entire fragment library were collected using in-house X-ray diffraction equipment.
This poster presents a summary of the results, demonstrating how Biofocus’s structural biology capabilities complement their range of fragment screening services.
High Throughput Rheological Characterization of Small Volume Biopharmaceutical FormulationsPoster
Importance of assessing viscosity fingerprints of small molecules.READ MORE
Applications of chemically modified synthetic guide RNA for CRISPR-Cas9 genome editingPoster
Our results indicate that MS modifications are required for experiments with co-electroporation of Cas9 mRNA and synthetic gRNA, yet have no impact on editing efficiency when delivered with lipid-based transfection reagents.READ MORE
The P450-Glo™ CYP2B6 Assay: a Rapid and Selective Assay for Measuring CYP2B6 Induction and InhibitionPoster
We have developed a luminogenic CYP2B6 assay for biochemical CYP2B6 inhibition and for cell-based CYP2B6 induction studies. Here we present the CYP2B6 luminogenic assay characterization and demonstrate its utility for measuring time dependent CYP2B6 inhibition, and for measuring CYP2B6 induction in cultured primary human hepatocytes with normalization to viable cell count.READ MORE